Carolyn Bertozzi Sells Shares in OmniAb, Inc. (OABI)
Insider Carolyn Bertozzi sold 20,000 shares of OmniAb, Inc. on June 17, 2026.
Key Points
- Insider Carolyn Bertozzi sold 20,000 shares of OmniAb, Inc. on June 17, 2026, with no disclosed transaction value.
- OmniAb's stock trades at $2.34 with a market cap of $339.2 million, and it has no meaningful P/E ratio due to negative earnings.
- Analysts maintain a positive outlook, with RBC Capital and Benchmark reiterating 'buy' ratings and setting price targets between $3 and $11.
On June 17, 2026, Carolyn Bertozzi sold 20,000 shares of OmniAb, Inc. (NasdaqGM: OABI). The transaction did not specify a value, and it was not part of a pre-planned trading program.
Other Institutional Activity in OmniAb
Several institutional investors have recently adjusted their positions in OmniAb. BlackRock, Inc. increased its holdings by 41,900 shares to a total of 8,106,881 shares, valued at about $12.7 million. Geode Capital Management, LLC added 202,887 shares, bringing its total to 2,925,579 shares worth roughly $4.6 million. Meanwhile, Cadian Capital Management, LP reduced its position by 277,825 shares, ending with 4,157,129 shares valued at approximately $6.5 million.
OmniAb, Inc. Stock Snapshot
Shares of OmniAb, Inc. are trading at $2.34. The company has a market cap of $339.2 million. Due to its negative earnings per share of -$0.46, it has no meaningful P/E ratio. The stock's beta is 1.146, indicating moderate volatility. Its 52-week range spans from $1.30 to $2.79, with a 50-day moving average of $1.97 and a 200-day moving average of $1.80.
Recent Earnings
For its recent quarter, OmniAb reported revenue of $28.9 million, showing a growth of 2.47%. However, the company faces a net margin of -187.6% and a return on equity of -20.25%. Investors will be watching closely for the next earnings report scheduled for August 6, 2026.
Insider Buying and Selling at OmniAb, Inc.
In addition to Carolyn Bertozzi's sale, other insiders made moves on June 17, 2026. Jennifer Cochran bought 40,000 shares and sold 20,000 shares, while John Higgins acquired 20,000 shares. These transactions were not part of any pre-arranged trading plans.
Analysts Set New Price Targets
Analysts remain optimistic about OmniAb's prospects. On March 27, 2025, RBC Capital maintained its 'buy' rating with a price target of $4. Benchmark reiterated its 'buy' rating on May 12, 2025, setting a target of $6. The consensus among six analysts is a 'buy' recommendation, with an average target price of $7.33.
About OmniAb, Inc.
OmniAb, Inc. is a biotechnology firm based in Emeryville, California. It provides discovery research technology to pharmaceutical and biotech companies, as well as academic institutions worldwide. The company's platform helps discover therapeutic antibodies and proteins, utilizing transgenic animals engineered to produce human-like antibodies. OmniAb's innovative technology supports drug development in the United States, Europe, Japan, China, and Canada.
Bottom Line
Insider transactions like Carolyn Bertozzi's sale can offer insights into company sentiment, though they don't necessarily predict stock performance. OmniAb's recent institutional activity and analyst ratings suggest continued interest in the stock despite its financial challenges. Investors will be keen to see how the company's strategic initiatives play out in the coming earnings report.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.